Orion Pharma (DHA:ORIONPHARM) Tariff Resilience Score: 0/10 (As of Jul. 03, 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
69 GF Score
Price BDT28.30
GF Value BDT20.29
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Tariff Resilience Score?

Orion Pharma has the Tariff Resilience Score of 0, which implies that the company might have .

Orion Pharma has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Orion Pharma might have .

Orion Pharma  (DHA:ORIONPHARM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Orion Pharma Tariff Resilience Score Related Terms

DHA:ORIONPHARM
69GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT28.30 is trading 39.5% above its estimated GF Value™ of BDT20.29. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Tariff Resilience Score: 0
  • GF Value™: BDT20.29 vs. price of BDT28.30 (39.5% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score

Get the complete analysis for DHA:ORIONPHARM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT28.30
Price
BDT20.29
GF Value